Cell-based immune anticipation of the omicron variant in SARS-CoV-2 triple-vaccinated cancer patients
Mario Mairhofer, Lea Kausche, Sabine Kaltenbrunner, Maria Pammer, Riad Ghanem, Maike Stegemann, Clemens A. Schmitt
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses · Immune responses and vaccinations
Main text
(iScience 28, 113727; November 21, 2025)
During copyediting, the production team erroneously changed the title from “Cell-based immune anticipation of the Omicron variant in SARS-CoV-2 triple-vaccinated cancer patients” to “Cell-based immune anticipation of the omicron variant in patients with SARS-CoV-2 triple-vaccinated cancer.” The title has now been corrected online. Production apologizes for any inconvenience and confusion caused.